OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITI
WJ Sandborn(Mayo Clinic in Arizona), C Gasink, Levinus A. Dieleman(University of North Carolina at Chapel Hill), Seymour Katz(New York University), Stephan R. Targan(Cedars-Sinai Medical Center), Shin‐Da Lee(China Medical University), L-L Gao(Janssen (United States)), Subrata Ghosh, P. Rutgeerts, Colombel Jf(Mount Sinai Hospital), S. B. Hanauer(University of Chicago), W de Villiers(University of Cape Town), B. Feagan, Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Jewel Johanns(Johnson & Johnson (United States))
Cited by 11
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k